What question did this study set out to answer?

This research investigates the role of PP2A in targeting MYCN for treating neuroblastoma.

January 17, 2026Cell Death and DiseaseOpen Access

PP2A activation targets MYCN in neuroblastoma

View Full Paper

Ask AI

Bookmark

Authors

Pharmacologic PP2A activation reduces MYCN expression in high-risk neuroblastoma, suggesting a potential therapy.

This research investigates the role of PP2A in targeting MYCN for treating neuroblastoma.
Utilized pharmacologic activation of PP2A with ATUX-1215 and ATUX-5800.
Analyzed changes in MYCN mRNA, protein expression, and phosphorylation levels.
Assessed the impact of PP2A activation on epigenetic modifications such as acetylation of H3K27.
Conducted in vivo studies to evaluate tumor growth in treated animal models.
PP2A activation led to reduced levels of MYCN mRNA and protein expression.
Acetylation of H3K27 at the MYCN promoter decreased significantly after treatment.
In vivo experiments showed decreased tumor growth in animals treated with ATUX-1215.
Confirmation of lower MYCN expression in analyzed tumor specimens.

Nazam et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark